TY - JOUR
T1 - Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands
T2 - insights from the ETNA-AF-Europe study
AU - de Vries, Tim A. C.
AU - Hemels, Martin E. W.
AU - Cools, Frank
AU - Crijns, Harry J. G. M.
AU - Yperzeele, Laetitia
AU - Vanacker, Peter
AU - Blankoff, Ivan
AU - Lancellotti, Patrizio
AU - Mairesse, Georges H.
AU - de Veer, Anne
AU - Casado Arroyo, Ruben
AU - Catez, Emmanuel
AU - de Pauw, Michel
AU - Vanassche, Thomas
AU - de Asmundis, Carlo
AU - Kirchhof, Paulus
AU - De Caterina, Raffaele
AU - de Groot, Joris R.
AU - ETNA-AF-Europe principal investigators from Belgium and the Netherlands
PY - 2021/7/4
Y1 - 2021/7/4
N2 - Background: Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban.Methods: With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 mL/min, weightResults: Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA(2)DS(2)-VASc (mean: 2.8 vs 3.2) and HAS-BLED scores (mean: 2.4 vs 2.6). Patients from BeNe less often had hypertension (61.6% vs 80.4%), and/or diabetes mellitus (17.3% vs 23.1%) than patients from OEC. Moreover, relatively fewer patients in BeNe were prescribed the reduced dose of 30 mg edoxaban (14.8%) than in OEC (25.4%). Overall, edoxaban was dosed according to label in 83.1% of patients. Yet, 30 mg edoxaban was prescribed in the absence of any dose reduction criteria in 36.9% of 30 mg users (5.5% of all patients) in BeNe compared with 35.5% (9.0% of all patients) in OEC.Conclusion: There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation.
AB - Background: Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban.Methods: With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 mL/min, weightResults: Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA(2)DS(2)-VASc (mean: 2.8 vs 3.2) and HAS-BLED scores (mean: 2.4 vs 2.6). Patients from BeNe less often had hypertension (61.6% vs 80.4%), and/or diabetes mellitus (17.3% vs 23.1%) than patients from OEC. Moreover, relatively fewer patients in BeNe were prescribed the reduced dose of 30 mg edoxaban (14.8%) than in OEC (25.4%). Overall, edoxaban was dosed according to label in 83.1% of patients. Yet, 30 mg edoxaban was prescribed in the absence of any dose reduction criteria in 36.9% of 30 mg users (5.5% of all patients) in BeNe compared with 35.5% (9.0% of all patients) in OEC.Conclusion: There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation.
KW - anticoagulants
KW - haemorrhage
KW - off-label use
KW - clinical trial
KW - phase IV
KW - stroke
KW - thromboembolism
U2 - 10.1080/00015385.2020.1746095
DO - 10.1080/00015385.2020.1746095
M3 - Article
C2 - 33406996
SN - 0001-5385
VL - 76
SP - 431
EP - 439
JO - Acta Cardiologica
JF - Acta Cardiologica
IS - 4
ER -